Bivalirudin Superior to Heparin for ACS Patients - Gregg W. Stone, MD

↳ This is a section part of Moment: CRT 2015 Coronary - The Thrombin Inhibitors Great Debate: Bivailrudin vs. Heparin

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$5.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Bivalirudin Superior to Heparin for ACS Patients presented by Gregg W. Stone, MD at CRT 2015

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$5.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Interventional Fellows

Session Name: The Thrombin Inhibitors Great Debate: Bivailrudin vs. Heparin

Track: Coronary

Learning Objectives

  • Update in advances in ACS & AMI Management

Other Components in this Moment

Overview
Bivalirudin Superior to Heparin for ACS Patients - Gregg W. Stone, MD
Heparin Should be the First-line Therapy for Patients with ACS/AMI - Cindy L. Grines, MD
Secondary Prevention Therapies for AMI Part I: Aspirin and ADP Antagonists - Deepak Bhatt, MD
Secondary Prevention Therapies for AMI Part 2: Thrombin Receptor Antagonists - Ori Ben-Yehuda, MD
Loading Simple Education